Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials

AI Generated Summary*

A Bayesian network meta-analysis compared complement inhibitors for geographic atrophy in age-related macular degeneration, pooling ten sham-controlled randomized trials (4,405 participants) of pegcetacoplan, avacincaptad pegol, lampalizumab, CLG561 and LFG316. Versus sham, 12-month lesion growth on fundus autofluorescence was significantly slower with avacincaptad pegol 2 mg (mean difference minus 0.58 mm²), monthly pegcetacoplan (minus 0.38 mm²) and every-other-month pegcetacoplan (minus 0.30 mm²), with avacincaptad pegol ranked first (SUCRA 93.55). No agent differed from sham in best-corrected visual acuity or serious adverse events, while monthly pegcetacoplan raised macular neovascularization odds (OR 4.30, 95% CrI 1.48 to 16.72). The authors conclude avacincaptad pegol 2 mg was the most effective agent and had better safety, acknowledging few trials and a one-year horizon.

*This summary was generated by AI and is published unedited. Oku does not alter these summaries. It may contain errors or omissions and is provided for general informational purposes only. Oku does not guarantee its accuracy, completeness, or reliability. For authoritative information, please refer to the original, peer-reviewed article.